Genomic mutation-driven metastatic breast cancer therapy: a single center experience
| Autor: | Susan L. Neuhausen, Joanne E. Mortimer, Yuan Yuan, Sumanta K. Pal, Paul Frankel, Ravi Salgia, Nicola M. Solomon, John H. Yim, Isa Mambetsariev, Yate-Ching Yuan, Susan E. Yost |
|---|---|
| Jazyk: | angličtina |
| Rok vydání: | 2017 |
| Předmět: |
0301 basic medicine
Oncology medicine.medical_specialty medicine.medical_treatment Bioinformatics Single Center Targeted therapy 03 medical and health sciences 0302 clinical medicine Internal medicine medicine next-generation sequencing (NGS) Triple-negative breast cancer Chemotherapy Performance status business.industry Cancer medicine.disease targeted therapy Metastatic breast cancer 3. Good health Clinical trial 030104 developmental biology 030220 oncology & carcinogenesis metastatic breast cancer (MBC) genomic profiling genomic mutation business Research Paper |
| Zdroj: | Oncotarget |
| ISSN: | 1949-2553 |
| Popis: | // Yuan Yuan 1 , Susan E. Yost 1 , John Yim 3 , Yate-Ching Yuan 2 , Nicola M. Solomon 1 , Isa Mambetsariev 1 , Sumanta Pal 1 , Paul Frankel 4 , Ravi Salgia 1 , Susan L. Neuhausen 5 and Joanne Mortimer 1 1 Department of Medical Oncology & Molecular Therapeutics, City of Hope Comprehensive Cancer Center and Beckman Research Institute, Duarte, CA, USA 2 Bioinformatics Core Facility, City of Hope Comprehensive Cancer Center and Beckman Research Institute, Duarte, CA, USA 3 Department of Surgery, City of Hope Comprehensive Cancer Center and Beckman Research Institute, Duarte, CA, USA 4 Department of Biostatistics, City of Hope Comprehensive Cancer Center and Beckman Research Institute, Duarte, CA, USA 5 Department of Population Sciences, City of Hope Comprehensive Cancer Center and Beckman Research Institute, Duarte, CA, USA Correspondence to: Yuan Yuan, email: yuyuan@coh.org Keywords: metastatic breast cancer (MBC), genomic profiling, genomic mutation, next-generation sequencing (NGS), targeted therapy Received: October 09, 2016 Accepted: December 26, 2016 Published: January 03, 2017 ABSTRACT Background : Next-Generation Sequencing (NGS) has made genomic mutation-driven therapy feasible for metastatic breast cancer (MBC) patients. We frequently submit tumor tissue from MBC patients for targeted NGS of tumor using the Illumina HiSeq 2000 platform (FoundationOne®, Foundation Medicine, MA). Herein, we report the results and clinical impact of this test in MBC patients. Patients and Methods : We identified patients with MBC treated at City of Hope from January 2014 to May 2016 who underwent NGS. Patients’ clinical characteristics, response to treatment (clinical assessment of tumor regression), and genomic mutation profiles were reviewed. Results : Forty-four patients with MBC underwent NGS: 24 triple negative breast cancer, 16 estrogen receptor positive, and 4 human epidermal growth factor receptor 2 positive patients. Twenty-three patients received more than three lines of chemotherapy prior to NGS. Actionable mutations (potentially responsive to targeted therapies that are on the market or in registered clinical trials) were identified in almost all patients (42/44; 95%) and over half of these 42 patients with actionable mutations (23/42; 55%) initiated mutation-driven targeted therapies. Of these 23 patients, 16/23 (70%) had assessable responses, and 7/23 (30%) were not assessable for response due to short exposure ( |
| Databáze: | OpenAIRE |
| Externí odkaz: |
|